Business
Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq
PARAMUS, NJ, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), today announced that shares of the Company’s common stock have been approved for listing on the Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “PLYX”. Shares of Polaryx common stock are expected
About this update from Polaryx Therapeutics, Inc.
[{"type":"image","alt":"Polaryx Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Polaryx Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/964835b700c9c0813d1c25e117cd2a32"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cjJ4aUxTnF9Z1M3DYFkWHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/964835b700c9c0813d1c25e117cd2a32","width":300,"height":50}},"lazy":false},{"type":"text","content":"PARAMUS, NJ, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), today announced that shares of the Company’s common stock have been approved for listing on the Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “PLYX”. Shares of Polaryx common stock are expected to commence trading on or about February 2, 2026.","length":549,"tagName":"p"},{"type":"text","content":"“We are excited and honored to have been approved for a direct listing on Nasdaq,” said Alex Yang, Polaryx’s Chairman and Chief Executive Officer. “This direct listing on one of the world’s leading stock market exchanges represents an important opportunity for Polaryx to reach a broad class of investors who share our dedication to delivering family-friendly therapies for pediatric patients fighting devastating rare orphan LSDs. It comes at a particularly important time in our development as we plan to launch SOTERIA, our single arm, open-label Phase 2 trial. This trial will assess our lead drug candidate PLX-200’s safety, tolerability, and clinical activity for multiple LSD indications to effectively address the tremendous unmet need in a basket trial design.”","length":770,"tagName":"p"},{"type":"text","content":"Maxim Group LLC acted as the exclusive financial advisor to Polaryx in connection with the direct listing. Gibson, Dunn & Crutcher LLP served as legal advisor and Brownstein Hyatt Farber Schreck, LLP served as Nevada counsel.","length":229,"tagName":"p"},{"type":"text","content":"The Company also announced plans to launch a new Investor Relations section on its website https://investors.pol...